Chronic Cannabinoid Receptor 2 Activation Reverses Paclitaxel Neuropathy Without Tolerance or Cannabinoid Receptor 1–Dependent Withdrawal

[1]  A. Lichtman,et al.  Cannabinoid CB2 Receptors Regulate Central Sensitization and Pain Responses Associated with Osteoarthritis of the Knee Joint , 2013, PloS one.

[2]  E. Walters,et al.  Induction of monocyte chemoattractant protein-1 (MCP-1) and its receptor CCR2 in primary sensory neurons contributes to paclitaxel-induced peripheral neuropathy. , 2013, The journal of pain : official journal of the American Pain Society.

[3]  P. Dougherty,et al.  Dynamic effects of TNF-α on synaptic transmission in mice over time following sciatic nerve chronic constriction injury. , 2013, Journal of neurophysiology.

[4]  Pál Pacher,et al.  Modulating the endocannabinoid system in human health and disease – successes and failures , 2013, The FEBS journal.

[5]  Xiaodong Na,et al.  The up-regulation of IL-6 in DRG and spinal dorsal horn contributes to neuropathic pain following L5 ventral root transection , 2013, Experimental Neurology.

[6]  S. A. Bura,et al.  Role of CB1 and CB2 cannabinoid receptors in the development of joint pain induced by monosodium iodoacetate , 2013, PAIN®.

[7]  R. Pertwee.  Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities , 2012, Philosophical Transactions of the Royal Society B: Biological Sciences.

[8]  J. Jallo,et al.  A cannabinoid type 2 receptor agonist attenuates blood–brain barrier damage and neurodegeneration in a murine model of traumatic brain injury , 2012, Journal of neuroscience research.

[9]  R. P. Landry,et al.  Spinal cannabinoid receptor type 2 agonist reduces mechanical allodynia and induces mitogen-activated protein kinase phosphatases in a rat model of neuropathic pain. , 2012, The journal of pain : official journal of the American Pain Society.

[10]  K. Müller-Vahl,et al.  The therapeutic potential of cannabis and cannabinoids. , 2012, Deutsches Arzteblatt international.

[11]  D. Simone,et al.  Cannabinoid Type-1 Receptor Reduces Pain and Neurotoxicity Produced by Chemotherapy , 2012, The Journal of Neuroscience.

[12]  D. Gomez-Nicola,et al.  Cannabinoid agonist WIN 55,212-2 prevents the development of paclitaxel-induced peripheral neuropathy in rats. Possible involvement of spinal glial cells. , 2012, European journal of pharmacology.

[13]  Leisha M. Armijo,et al.  Intrathecal cannabilactone CB2R agonist, AM1710, controls pathological pain and restores basal cytokine levels , 2012, PAIN®.

[14]  D. Cogdell,et al.  Prevention of Paclitaxel-Induced Neuropathy Through Activation of the Central Cannabinoid Type 2 Receptor System , 2012, Anesthesia and analgesia.

[15]  P. Dougherty,et al.  Evidence that spinal astrocytes but not microglia contribute to the pathogenesis of Paclitaxel-induced painful neuropathy. , 2012, The journal of pain : official journal of the American Pain Society.

[16]  A. Hohmann,et al.  The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB2 receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy , 2012, Molecular pain.

[17]  J. Crystal,et al.  Self-medication of a cannabinoid CB2 agonist in an animal model of neuropathic pain , 2011, PAIN.

[18]  C. Loprinzi,et al.  Chemotherapy‐Induced Peripheral Neuropathy: Prevention and Treatment , 2011, Clinical pharmacology and therapeutics.

[19]  J. P. de Rivero Vaccari,et al.  Functional Recovery after Peripheral Nerve Injury is Dependent on the Pro-Inflammatory Cytokines IL-1β and TNF: Implications for Neuropathic Pain , 2011, The Journal of Neuroscience.

[20]  H. Neelakantan,et al.  Cannabidiol Prevents the Development of Cold and Mechanical Allodynia in Paclitaxel-Treated Female C57Bl6 Mice , 2011, Anesthesia and analgesia.

[21]  M. Barbe,et al.  Acute effects of a selective cannabinoid-2 receptor agonist on neuroinflammation in a model of traumatic brain injury. , 2011, Journal of neurotrauma.

[22]  Z. Xi,et al.  Brain Cannabinoid CB2 Receptors Modulate Cocaine’s Actions in Mice , 2011, Nature Neuroscience.

[23]  A. Hohmann,et al.  Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: Antinociception without central nervous system side-effects , 2011, Pharmacology Biochemistry and Behavior.

[24]  Zhen-Zhong Xu,et al.  TNF-alpha contributes to spinal cord synaptic plasticity and inflammatory pain: Distinct role of TNF receptor subtypes 1 and 2 , 2011, PAIN®.

[25]  D. Selley,et al.  The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects , 2011, Neuropharmacology.

[26]  P. Chandran,et al.  Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats , 2011, British journal of pharmacology.

[27]  P. Dougherty,et al.  A p38 Mitogen-Activated Protein Kinase-Dependent Mechanism of Disinhibition in Spinal Synaptic Transmission Induced by Tumor Necrosis Factor-α , 2010, The Journal of Neuroscience.

[28]  P. Diaz,et al.  Pharmacological Characterization of a Novel Cannabinoid Ligand, MDA19, for Treatment of Neuropathic Pain , 2010, Anesthesia and analgesia.

[29]  K. Mackie,et al.  CB2: a cannabinoid receptor with an identity crisis , 2010, British journal of pharmacology.

[30]  I. Bechmann,et al.  R-Flurbiprofen Reduces Neuropathic Pain in Rodents by Restoring Endogenous Cannabinoids , 2010, PloS one.

[31]  A. Rissanen,et al.  A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study , 2010, International Journal of Obesity.

[32]  P. Lazzari,et al.  1-(2′,4′-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice , 2010, Neurobiology of Disease.

[33]  A. Hohmann,et al.  The endocannabinoid system and pain. , 2009, CNS & neurological disorders drug targets.

[34]  E. Brouillet,et al.  Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington's disease , 2009, Glia.

[35]  Zhen-Zhong Xu,et al.  JNK-Induced MCP-1 Production in Spinal Cord Astrocytes Contributes to Central Sensitization and Neuropathic Pain , 2009, The Journal of Neuroscience.

[36]  G. Fox,et al.  Characterization of a Cannabinoid CB2 Receptor-Selective Agonist, A-836339 [2,2,3,3-Tetramethyl-cyclopropanecarboxylic Acid [3-(2-Methoxy-ethyl)-4,5-dimethyl-3H-thiazol-(2Z)-ylidene]-amide], Using in Vitro Pharmacological Assays, in Vivo Pain Models, and Pharmacological Magnetic Resonance Imaging , 2009, Journal of Pharmacology and Experimental Therapeutics.

[37]  H. Pan,et al.  Cannabidiol Attenuates Cisplatin-Induced Nephrotoxicity by Decreasing Oxidative/Nitrosative Stress, Inflammation, and Cell Death , 2008, Journal of Pharmacology and Experimental Therapeutics.

[38]  P. Vivas-Mejia,et al.  MDA7: a novel selective agonist for CB2 receptors that prevents allodynia in rat neuropathic pain models , 2008, British journal of pharmacology.

[39]  N. Kiguchi,et al.  Up-regulation of tumor necrosis factor-alpha in spinal cord contributes to vincristine-induced mechanical allodynia in mice , 2008, Neuroscience Letters.

[40]  J. Alferink,et al.  Crucial Role of CB2 Cannabinoid Receptor in the Regulation of Central Immune Responses during Neuropathic Pain , 2008, The Journal of Neuroscience.

[41]  A. Hohmann,et al.  Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats , 2008, Journal of Pharmacology and Experimental Therapeutics.

[42]  I. Chessell,et al.  The putative cannabinoid receptor GPR55 plays a role in mechanical hyperalgesia associated with inflammatory and neuropathic pain , 2008, PAIN.

[43]  R. Ji,et al.  Cytokine Mechanisms of Central Sensitization: Distinct and Overlapping Role of Interleukin-1β, Interleukin-6, and Tumor Necrosis Factor-α in Regulating Synaptic and Neuronal Activity in the Superficial Spinal Cord , 2008, The Journal of Neuroscience.

[44]  J. Deleo,et al.  Spinal Microglial and Perivascular Cell Cannabinoid Receptor Type 2 Activation Reduces Behavioral Hypersensitivity without Tolerance after Peripheral Nerve Injury , 2008, Anesthesiology.

[45]  T. Mikami,et al.  Involvement of central cannabinoid CB2 receptor in reducing mechanical allodynia in a mouse model of neuropathic pain. , 2008, European journal of pharmacology.

[46]  Wolfgang Grisold,et al.  Chemotherapy‐induced neuropathy , 2008, Journal of the peripheral nervous system : JPNS.

[47]  C. George,et al.  Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. , 2007, Journal of medicinal chemistry.

[48]  A. Hohmann,et al.  Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats , 2007, British journal of pharmacology.

[49]  V. Chapman,et al.  Cannabinoid CB2 Receptor-Mediated Anti-nociception in Models of Acute and Chronic Pain , 2007, Molecular Neurobiology.

[50]  M. Glass,et al.  The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. , 2007, Current neuropharmacology.

[51]  Ji-Tian Xu,et al.  Tumor necrosis factor-α induces long-term potentiation of C-fiber evoked field potentials in spinal dorsal horn in rats with nerve injury: The role of NF-kappa B, JNK and p38 MAPK , 2007, Neuropharmacology.

[52]  G. Pryce,et al.  Control of Spasticity in a Multiple Sclerosis Model is mediated by CB1, not CB2, Cannabinoid Receptors , 2007, British journal of pharmacology.

[53]  Ji-Tian Xu,et al.  The role of tumor necrosis factor-alpha in the neuropathic pain induced by Lumbar 5 ventral root transection in rat , 2006, PAIN.

[54]  Hideyuki Okano,et al.  Conditional ablation of Stat3 or Socs3 discloses a dual role for reactive astrocytes after spinal cord injury , 2006, Nature Medicine.

[55]  P. McIntyre,et al.  Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons , 2005, Neuroscience.

[56]  E. Ponomarev,et al.  Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli , 2005, Journal of neurochemistry.

[57]  R. LaMotte,et al.  Excitatory monocyte chemoattractant protein-1 signaling is up-regulated in sensory neurons after chronic compression of the dorsal root ganglion. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[58]  D. R. Sagar,et al.  Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats , 2005, The European journal of neuroscience.

[59]  M. Cebeira,et al.  Cannabinoid tolerance and dependence: A review of studies in laboratory animals , 2005, Pharmacology Biochemistry and Behavior.

[60]  L. Koetzner,et al.  Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy , 2005, Neuropharmacology.

[61]  A. Hohmann,et al.  Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. , 2004, Journal of neurophysiology.

[62]  V. Chapman,et al.  Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naïve rats and in rat models of inflammatory and neuropathic pain , 2004, The European journal of neuroscience.

[63]  R. Myers,et al.  TNF-&agr; and TNF-&agr; Receptor Type 1 Upregulation in Glia and Neurons After Peripheral Nerve Injury: Studies in Murine DRG and Spinal Cord , 2004 .

[64]  J. de Vry,et al.  Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development , 2004, Behavioural pharmacology.

[65]  Alberto Rábano,et al.  Cannabinoid CB2 Receptors and Fatty Acid Amide Hydrolase Are Selectively Overexpressed in Neuritic Plaque-Associated Glia in Alzheimer's Disease Brains , 2003, The Journal of Neuroscience.

[66]  T. Vanderah,et al.  Inhibition of Inflammatory Hyperalgesia by Activation of Peripheral CB2 Cannabinoid Receptors , 2003, Anesthesiology.

[67]  C. Fairbanks.  Spinal delivery of analgesics in experimental models of pain and analgesia. , 2003, Advanced drug delivery reviews.

[68]  D. Cockayne,et al.  Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[69]  A. Hohmann,et al.  Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation , 2003, Neuroscience.

[70]  S. Goldberg,et al.  Cannabinoids: reward, dependence, and underlying neurochemical mechanisms—a review of recent preclinical data , 2003, Psychopharmacology.

[71]  T. Groblewski,et al.  Induction of CB2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models , 2003, The European journal of neuroscience.

[72]  P. Mcgeer,et al.  Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid‐type CB2 receptor , 2003, British journal of pharmacology.

[73]  L. Sorkin,et al.  Tumor Necrosis Factor-α Induces Mechanical Allodynia after Spinal Nerve Ligation by Activation of p38 MAPK in Primary Sensory Neurons , 2003, The Journal of Neuroscience.

[74]  Y. Üresin,et al.  Comparison of the effects of specific and nonspecific inhibition of nitric oxide synthase on morphine analgesia, tolerance and dependence in mice , 2003 .

[75]  A. Lichtman,et al.  Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice. , 2001, The Journal of pharmacology and experimental therapeutics.

[76]  T. Vanderah,et al.  CB2 cannabinoid receptor-mediated peripheral antinociception , 2001, Pain.

[77]  T Seppälä,et al.  Morphine-Induced Dependence and Sensitization Are Altered in Mice Deficient in AMPA-Type Glutamate Receptor-A Subunits , 2001, The Journal of Neuroscience.

[78]  C. Bass,et al.  Time course for the induction and maintenance of tolerance to Δ9-tetrahydrocannabinol in mice , 2000 .

[79]  H. Junger,et al.  Nociceptive and inflammatory effects of subcutaneous TNFα , 2000, Pain.

[80]  H. McQuay.  Opioids in pain management , 1999, The Lancet.

[81]  M. Parmentier,et al.  Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. , 1999, Science.

[82]  J. Lowe,et al.  CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol. , 1998, The Journal of pharmacology and experimental therapeutics.

[83]  S. Welch.  Characterization of anandamide-induced tolerance: comparison to delta 9-THC-induced interactions with dynorphinergic systems. , 1997, Drug and alcohol dependence.

[84]  R. Myers,et al.  Endoneurial injection of TNF-α produces neuropathic pain behaviors , 1996 .

[85]  J. Lowe,et al.  Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal. , 1996, The Journal of pharmacology and experimental therapeutics.

[86]  S. L. Patrick,et al.  Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. , 1995, European journal of pharmacology.

[87]  L. Melvin,et al.  Development of cross-tolerance between delta 9-tetrahydrocannabinol, CP 55,940 and WIN 55,212. , 1994, The Journal of pharmacology and experimental therapeutics.

[88]  M. Zimmermann,et al.  Ethical guidelines for investigations of experimental pain in conscious animals , 1983, Pain.

[89]  H. Bradshaw,et al.  Alterations in endocannabinoid tone following chemotherapy-induced peripheral neuropathy: effects of endocannabinoid deactivation inhibitors targeting fatty-acid amide hydrolase and monoacylglycerol lipase in comparison to reference analgesics following cisplatin treatment. , 2013, Pharmacological research.

[90]  L. Menéndez,et al.  THEMED ISSUE: CANNABINOIDS RESEARCH PAPER Spinal and peripheral analgesic effects of the CB2 cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain , 2010 .

[91]  A. Lichtman,et al.  Cannabinoid tolerance and dependence. , 2005, Handbook of experimental pharmacology.